Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Long-term benefits of TUMT (transurethral microwave thermotherapy) unproven, says Swedish council

This article was originally published in Clinica

Executive Summary

Although scientific documentation for the short-term effects of high energy transurethral microwave thermotherapy (TUMT) in the treatment of benign prostate hypertrophy (BPH) exists, few studies have been carried out on long-term benefits to patients, claims a new report by the Swedish council on technology assessment in health care (SBU). In addition to this, there has been no cost analysis of high energy TUMT in comparison with other treatment methods, says SBU in an alert issued last week.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel